Literature DB >> 18236042

A33 antigen displays persistent surface expression.

Margaret E Ackerman1, Cecile Chalouni, Michael M Schmidt, Vivek V Raman, Gerd Ritter, Lloyd J Old, Ira Mellman, K Dane Wittrup.   

Abstract

The A33 antigen is a cell surface glycoprotein of the small intestine and colonic epithelium with homology to tight junction-associated proteins of the immunoglobulin superfamily, including CAR and JAM. Its restricted tissue localization and high level of expression have led to its use as a target in colon cancer immunotherapy. Although the antigen is also present in normal intestine, radiolabeled antibodies against A33 are selectively retained by tumors in the gut as well as in metastatic lesions for as long as 6 weeks. Accordingly, we have studied the trafficking and kinetic properties of the antigen to determine its promise in two-step, pretargeted therapies. The localization, mobility, and persistence of the antigen were investigated, and this work has demonstrated that the antigen is both highly immobile and extremely persistent-retaining its surface localization for a turnover halflife of greater than 2 days. In order to explain these unusual properties, we explored the possibility that A33 is a component of the tight junction. The simple property of surface persistence, described here, may contribute to the prolonged retention of the clinically administered antibodies, and their uncommon ability to penetrate solid tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18236042      PMCID: PMC2836164          DOI: 10.1007/s00262-007-0433-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  51 in total

1.  Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression.

Authors:  Cameron N Johnstone; Sara J White; Niall C Tebbutt; Fiona J Clay; Matthias Ernst; William H Biggs; Carrie S Viars; Suzanne Czekay; Karen C Arden; Joan K Heath
Journal:  J Biol Chem       Date:  2002-07-11       Impact factor: 5.157

Review 2.  The JAM family of proteins.

Authors:  Kenneth J Mandell; Charles A Parkos
Journal:  Adv Drug Deliv Rev       Date:  2005-04-25       Impact factor: 15.470

Review 3.  Recent advances in pretargeted radioimmunotherapy.

Authors:  A Gruaz-Guyon; O Raguin; J Barbet
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

4.  A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.

Authors:  Andrew M Scott; Fook-Thean Lee; Robert Jones; Wendie Hopkins; Duncan MacGregor; Jonathan S Cebon; Anthony Hannah; Geoffrey Chong; Paul U; Anthony Papenfuss; Angela Rigopoulos; Susan Sturrock; Roger Murphy; Veronika Wirth; Carmel Murone; Fiona E Smyth; Simon Knight; Sydney Welt; Gerd Ritter; Elizabeth Richards; Edouard C Nice; Antony W Burgess; Lloyd J Old
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

Review 5.  Pretargeted radioimmunotherapy of cancer: progress step by step.

Authors:  Otto C Boerman; Frank G van Schaijk; Wim J G Oyen; Frans H M Corstens
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

Review 6.  The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.

Authors:  S Hammarström
Journal:  Semin Cancer Biol       Date:  1999-04       Impact factor: 15.707

7.  Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33.

Authors:  G Ritter; L S Cohen; C Williams; E C Richards; L J Old; S Welt
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

8.  Rapid diffusion of green fluorescent protein in the mitochondrial matrix.

Authors:  A Partikian; B Olveczky; R Swaminathan; Y Li; A S Verkman
Journal:  J Cell Biol       Date:  1998-02-23       Impact factor: 10.539

9.  An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier".

Authors:  W van Osdol; K Fujimori; J N Weinstein
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

10.  Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions.

Authors:  M Furuse; M Itoh; T Hirase; A Nagafuchi; S Yonemura; S Tsukita; S Tsukita
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

View more
  32 in total

1.  124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.

Authors:  Joseph A O'Donoghue; Peter M Smith-Jones; John L Humm; Shutian Ruan; Daniel A Pryma; Achim A Jungbluth; Chaitanya R Divgi; Jorge A Carrasquillo; Neeta Pandit-Taskar; Yuman Fong; Vivian E Strong; Nancy E Kemeny; Lloyd J Old; Steven M Larson
Journal:  J Nucl Med       Date:  2011-11-08       Impact factor: 10.057

2.  A mechanistic compartmental model for total antibody uptake in tumors.

Authors:  Greg M Thurber; K Dane Wittrup
Journal:  J Theor Biol       Date:  2012-09-06       Impact factor: 2.691

3.  Harnessing the bioorthogonal inverse electron demand Diels-Alder cycloaddition for pretargeted PET imaging.

Authors:  Thomas Reiner; Jason S Lewis; Brian M Zeglis
Journal:  J Vis Exp       Date:  2015-02-03       Impact factor: 1.355

4.  (124)I-huA33 antibody PET of colorectal cancer.

Authors:  Jorge A Carrasquillo; Neeta Pandit-Taskar; Joseph A O'Donoghue; John L Humm; Pat Zanzonico; Peter M Smith-Jones; Chaitanya R Divgi; Daniel A Pryma; Shutian Ruan; Nancy E Kemeny; Yuman Fong; Douglas Wong; Jaspreet S Jaggi; David A Scheinberg; Mithat Gonen; Katherine S Panageas; Gerd Ritter; Achim A Jungbluth; Lloyd J Old; Steven M Larson
Journal:  J Nucl Med       Date:  2011-07-15       Impact factor: 10.057

5.  Reactive polymer enables efficient in vivo bioorthogonal chemistry.

Authors:  Neal K Devaraj; Greg M Thurber; Edmund J Keliher; Brett Marinelli; Ralph Weissleder
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-12       Impact factor: 11.205

6.  68Ga chelating bioorthogonal tetrazine polymers for the multistep labeling of cancer biomarkers.

Authors:  Brandon Nichols; Zhengtao Qin; Jun Yang; David R Vera; Neal K Devaraj
Journal:  Chem Commun (Camb)       Date:  2014-03-04       Impact factor: 6.222

7.  Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.

Authors:  Brian M Zeglis; Christian Brand; Dalya Abdel-Atti; Kathryn E Carnazza; Brendon E Cook; Sean Carlin; Thomas Reiner; Jason S Lewis
Journal:  Mol Pharm       Date:  2015-08-31       Impact factor: 4.939

8.  Noise suppressed, multifocus image fusion for enhanced intraoperative navigation.

Authors:  Paolo Fumene Feruglio; Claudio Vinegoni; Lioubov Fexon; Greg Thurber; Andrea Sbarbati; Ralph Weissleder
Journal:  J Biophotonics       Date:  2012-08-06       Impact factor: 3.207

9.  A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry.

Authors:  Brian M Zeglis; Kuntal K Sevak; Thomas Reiner; Priya Mohindra; Sean D Carlin; Pat Zanzonico; Ralph Weissleder; Jason S Lewis
Journal:  J Nucl Med       Date:  2013-05-24       Impact factor: 10.057

10.  Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability.

Authors:  Michael M Schmidt; Greg M Thurber; K Dane Wittrup
Journal:  Cancer Immunol Immunother       Date:  2008-04-12       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.